NEW YORK (GenomeWeb) – Rheonix today said that it has raised $28.6 million in order to ramp up commercialization of its Encompass MDx and Encompass Optimum molecular diagnostic testing platforms. 

According to a document filed with the US Securities and Exchange Commission, the company is targeting $36.5 million for the financing round. Rheonix did not disclose the identities of the investors. 

Rand Capital and Cayuga Venture Fund co-lead the offering and was joined by existing investors Advantage Capital Partners and Gefinor Capital. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.